文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

人工智能揭示加替沙星、吡嗪酰胺和利福平在肺结核治疗中的三向浓度依赖性拮抗

Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该研究嵌套于OFLOTUB试验,对126例药物敏感肺结核患者进行药代动力学分析和机器学习建模,随访24个月。结果显示吡嗪酰胺和利福平的峰浓度及AUC重要性高于加替沙星,并发现三种药物浓度间存在三向拮抗作用;当利福平峰浓度高于7 mg/L时该负交互作用消失。

要点

  • 吡嗪酰胺和利福平的浓度对治疗结局的影响大于加替沙星。
  • 三种药物浓度间存在三向拮抗,利福平峰浓度>7 mg/L时拮抗消失。
  • 提高利福平和加替沙星剂量可能改善治疗结局。

核心结论

  • 浓度依赖性拮抗导致死亡、复发和治疗失败,但高利福平浓度可消除该拮抗。
  • 因此,提高利福平和加替沙星剂量可能改善疗效。

研究设计与样本

  • 研究嵌套于OFLOTUB试验,患者随访24个月,用spoligotyping确定复发。
  • 治疗前2个月中2天采血测药物浓度,进行房室PK分析。
  • 纳入126例患者,利用27个临床和实验室特征通过机器学习集成方法识别治疗失败的预测因子。

主要发现

  • 126例患者中95例(75%)结局良好,19例(15%)治疗失败、复发或死亡。
  • 吡嗪酰胺和利福平的峰浓度及AUC重要性排名高于加替沙星AUC。
  • 药物浓度在南非和西非试验点间分布及排名差异显著,但分别解释结局变异的31%和75%。
  • 发现吡嗪酰胺、加替沙星和利福平浓度的三向拮抗交互作用。
  • 当利福平峰浓度高于7 mg/L时,这些负交互作用消失。

关键数值与推荐

  • 治疗失败定义为治疗结束时持续痰培养未转阴、随访期间复发或死亡。
  • 利福平峰浓度高于7 mg/L时三向拮抗消失。

临床怎么用

  • 临床可考虑提高利福平和加替沙星剂量以改善肺结核治疗结局,尤其需关注利福平峰浓度是否高于7 mg/L。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the experimental arm of the OFLOTUB trial, gatifloxacin replaced ethambutol in the standard 4-month regimen for drug-susceptible pulmonary tuberculosis. The study included a nested pharmacokinetic (PK) study. We sought to determine if PK variability played a role in patient outcomes. METHODS: Patients recruited in the trial were followed for 24 months, and relapse ascertained using spoligotyping. Blood was drawn for drug concentrations on 2 separate days during the first 2 months of therapy, and compartmental PK analyses was performed. Failure to attain sustained sputum culture conversion at the end of treatment, relapse, or death during follow-up defined therapy failure. In addition to standard statistical analyses, we utilized an ensemble of machine-learning methods to identify patterns and predictors of therapy failure from among 27 clinical and laboratory features. RESULTS: Of 126 patients, 95 (75%) had favorable outcomes and 19 (15%) failed therapy, relapsed, or died. Pyrazinamide and rifampicin peak concentrations and area under the concentration-time curves (AUCs) were ranked higher (more important) than gatifloxacin AUCs. The distribution of individual drug concentrations and their ranking varied significantly between South African and West African trial sites; however, drug concentrations still accounted for 31% and 75% of variance of outcomes, respectively. We identified a 3-way antagonistic interaction of pyrazinamide, gatifloxacin, and rifampicin concentrations. These negative interactions disappeared if rifampicin peak concentration was above 7 mg/L. CONCLUSIONS: Concentration-dependent antagonism contributed to death, relapse, and therapy failure but was abrogated by high rifampicin concentrations. Therefore, increasing both rifampin and gatifloxacin doses could improve outcomes. CLINICAL TRIALS REGISTRATION: NCT00216385.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Pasipanodya JG, Smythe W, Merle CS, et al. Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis. Clin Infect Dis. 2018. PMID: 30496458. doi:10.1093/cid/ciy610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。